Details for New Drug Application (NDA): 022256
✉ Email this page to a colleague
The generic ingredient in SAVELLA is milnacipran hydrochloride. There are twenty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the milnacipran hydrochloride profile page.
Summary for 022256
Tradename: | SAVELLA |
Applicant: | Abbvie |
Ingredient: | milnacipran hydrochloride |
Patents: | 1 |
Pharmacology for NDA: 022256
Mechanism of Action | Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors |
Suppliers and Packaging for NDA: 022256
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256 | NDA | Allergan, Inc. | 0456-1500 | 0456-1500-55 | 1 BLISTER PACK in 1 CARTON (0456-1500-55) / 1 KIT in 1 BLISTER PACK |
SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256 | NDA | Allergan, Inc. | 0456-1510 | 0456-1510-60 | 60 TABLET, FILM COATED in 1 BOTTLE (0456-1510-60) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 12.5MG | ||||
Approval Date: | Jan 14, 2009 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Sep 19, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | MANAGEMENT OF FIBROMYALGIA |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 25MG | ||||
Approval Date: | Jan 14, 2009 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Sep 19, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | MANAGEMENT OF FIBROMYALGIA |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
Approval Date: | Jan 14, 2009 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Sep 19, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | MANAGEMENT OF FIBROMYALGIA |
Expired US Patents for NDA 022256
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-002 | Jan 14, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-004 | Jan 14, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-001 | Jan 14, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-004 | Jan 14, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-003 | Jan 14, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-003 | Jan 14, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-004 | Jan 14, 2009 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription